Background: To assess the association between radiation therapy (RT) use and overall survival (OS) for patients with metastatic head and neck squamous cell carcinomas (HNSCC). Methods: We analyzed the National Cancer Database to identify patients with newly diagnosed metastatic HNSCC from 2004 to 2013 who were treated with upfront chemotherapy. Associations between the use of RT and OS were evaluated. Results: We identified 3516 patients with metastatic HNSCC who were treated with chemotherapy; 2288 (65%) were also treated with RT. The addition of RT to chemotherapy was associated with prolonged survival (median: 13.6 vs 11.3 months, log-rank P < .001). After adjusting for other prognostic factors in a multivariable Cox model, propensity score matching and landmark analyses limited to patients who survived at least 3, 6, and 12 months after diagnosis, the use of RT remained associated with prolonged survival. Conclusion: The addition of RT to chemotherapy in the up-front management of metastatic HNSCC was associated with prolonged OS in this study.
| INTRODUCTION
The advent of multimodality treatment has significantly transformed the management of patients with locoregionally advanced head and neck squamous cell carcinomas (HNSCC). [1] [2] [3] However, for patients with distant metastatic HNSCC, outcomes remain dismal and little progress has been made in improving overall survival (OS). 4 Although systemic therapy alone has traditionally been considered in this setting, response rates have been poor, with nearly all patients dying of disease progression within months. [5] [6] [7] Radiation therapy (RT) plays a significant role in the management of nonmetastatic HNSCC. Radiation delivered postoperatively in the adjuvant setting significantly improves locoregional control, and organ-sparing approaches for pharyngeal and laryngeal cancers that rely on radiation as the primary treatment modality yield high rates of disease control. 8 In addition, technological advancements in the delivery of RT with the use of intensity modulated radiation therapy have resulted in improvements in quality of life (QOL) for patients with HNSCC. 9, 10 Although RT plays a critical role in the definitive management of locoregionally advanced HNSCC, its role in patients with initial distant metastatic disease at diagnosis is not clearly defined. This is an uncommon scenario and therefore data in this setting are limited. Given that the majority of patients with distant metastatic HNSCC present with symptomatic locoregional disease and Rafi Kabarriti and Sujith Baliga contributed equally to this article.
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die of primary tumor progression, [11] [12] [13] we hypothesized that the addition of RT to the initial management of these patients may have an impact on survival. In this study, we analyzed the National Cancer Database (NCDB) to determine if the addition of RT to chemotherapy could improve OS in patients with distant metastatic HNSCC.
| METHODS
The NCDB is a joint project of the Commission on Cancer of the American College of Surgeons and the American Cancer Society. The Commission on Cancer's NCDB and the hospitals participating in the Commission on Cancer NCDB are the source of the de-identified data used herein; they have not verified and are not responsible for the statistical validity of the data analysis or the conclusions derived by the authors. Data within the NCDB include basic demographics, cancer staging, comorbidities, therapies delivered during the first course of treatment, and OS. We utilized the NCDB to identify patients with newly diagnosed head and neck cancer from [2004] [2005] [2006] [2007] [2008] [2009] [2010] [2011] [2012] [2013] . Patients who met the following inclusion criteria were included: (1) Primary head and neck cancer of the lip, tongue, floor of mouth, gum and other mouth, nasopharynx, tonsil, oropharynx, hypopharynx, salivary gland, other oral cavity and pharynx, and larynx; (2) ≥18 years; (3) metastatic disease using the American Joint Committee on Cancer Staging Manual; (4) squamous cell carcinoma histology. Patients were excluded if they met the following criteria: (1) died within 30 days of diagnosis; (2) did not receive chemotherapy; (3) received surgery to the head and neck; (4) had incomplete datasets for RT, chemotherapy, or CharlsonDeyo comorbidity score; (5) had missing information for survival time; (6) treated with radiotherapy to an area that was not in the head and neck (Figure 1 ). Patients were subsequently stratified and analyzed according to whether they received RT or not in the initial management of their metastatic HNSCC.
The primary objective for this study was to test whether patients with metastatic HNSCC who received head and neck RT in addition to chemotherapy had improved OS compared to patients treated with chemotherapy alone. Given that the use of chemotherapy is considered as part of the standard of care for patients with unresectable metastatic HNSCC, we felt that patients who were treated with chemotherapy alone were an appropriate control group for this study. OS was calculated from the date of diagnosis.
To adjust for nonrandom patient assignment for the use of RT that may have been influenced by patient and/or disease-related characteristics potentially confounding survival estimates, we performed propensity score analysis. Propensity scores were generated using multivariate logistic regression with the exposure variable (RT) as the intervention of interest, and then subsequently compared the matched samples with OS as the outcome of interest. A 1:1 propensity score matching was used to match patients who received RT to those that did not, not allowing replacement and using a caliper width equal to the SD of the logit of the propensity score multiplied by 0.20.
For each case control analysis, the following variables were included: age, sex, race, primary site of disease (grouped into oral cavity, nasopharynx, oropharynx, larynx, or hypopharynx), T classification, N classification, diagnosis period, facility type, distance from facility, income, Charlson/Deyo comorbidity score, sites of metastasis (lung, liver, bone, or brain), chemotherapy administration (multiagent vs single agent), and immunotherapy. Kaplan-Meier curves for OS were generated for patients who received RT and those that did not. Comparisons were made using proportional hazards modeling.
Baseline characteristics for the entire cohort as well as for propensity matched cohorts were compared using the chi-square test for categorical variables and the MannWhitney U for continuous variables.
Secondary analyses of the unmatched datasets were performed. Bivariate analysis using Cox proportional hazards modeling was used to assess each of the following variables as predictors of OS: age, sex, race, primary site of disease (grouped into oral cavity, nasopharynx, oropharynx, larynx, or hypopharynx), T classification, N classification, diagnosis period, facility type, distance from facility, income, insurance status, Charlson/Deyo comorbidity score, sites of metastasis (lung, liver, bone, or brain), chemotherapy administration (multiagent vs single agent), extent of metastasis (1 organ vs ≥2 organs from the following: lung, liver, bone, or brain), immunotherapy, and RT use. Each of these variables was also tested as an independent predictor of OS using backward stepwise multivariate Cox regression. Backward elimination was halted once all remaining independent variables were associated with P values below .05.
To account for potential biases favoring the administration of RT to patients with more favorable baseline prognosis, sequential landmark analyses evaluating survival with and without RT were performed for patients surviving a minimum of 3, 6, and 12 months from diagnosis. To explore whether the association between treatment with RT and OS is consistent across different primary sites (oral cavity, nasopharynx, oropharynx, larynx, or hypopharynx), we built reduced multivariable Cox proportional hazards OS models for each primary site. Covariates that were statistically significantly associated with OS in the initial model were included in the reduced models. A Forest plot depicting the adjusted hazard ratios for treatment with RT as a predictor of OS was generated. The likelihood ratio test was used to examine interactions between treatment with RT and primary site as predictors of OS.
To evaluate the effect of RT dose on survival, we calculated the biologically effective dose for each patient that received RT using the equation nd(1 + d/α/β) in which n is the number of fractions, d is the dose/fraction, and α/β was assumed to be 10 for head and neck cancers. As a biologically effective dose (BED) of at least 72 Gy 10 is needed to achieve long-term local control, we compared the effect of delivering BED doses of 72 Gy 10 or higher on OS to that of lower doses. The BED of 72 Gy 10 was chosen a priori based on clinical data demonstrating the need for these doses (approximately 60 Gy in 30 fractions) 14 to achieve adequate local control. Patients were excluded from the BED analysis if they had nonsensical doses such as doses >200 Gy or if they did not have a RT dose specified. P values <.05 were considered statistically significant for all analyses. Statistical analyses were performed using STATA version 12.1 and customized scripts in Matlab (The Mathworks, Natick, Massachusetts).
| RESULTS
We identified 310,195 patients diagnosed with head and neck cancer from 2004 to 2013, of which 10,240 (3.3%) had distant metastatic disease and met inclusion criteria ( Figure 1 ). Patients were subsequently excluded if they had nonsquamous histology (n = 2657), had surgery to the head and neck performed (n = 903), or if they died within 30 days of diagnosis (n = 481). We then excluded patients who did not receive chemotherapy (n = 2083), had no follow-up time recorded (n = 443), or if they received RT to a site other than the head and neck (n = 157). Our final dataset comprised 3516 patients, of which 2288 (65%) received RT and 1228 (35%) that did not (Supporting Information Figure S1 ). Of patients with received RT and chemotherapy, 1069 (46.7%) were treated concurrently with RT, 943 (41.2%) received RT followed by chemotherapy, and 276 (12.1%) received chemotherapy followed by RT. The baseline pretreatment demographic, socioeconomic, and tumor characteristics are presented in Table 1 .
On logistic regression analysis, age, primary site, diagnosis year, distance, facility type, use of immunotherapy, chemotherapy administration (single vs multiagent), T classification, and N classification were associated with the use of RT. Compared to treatment at academic centers, those treated at community centers were more likely to be treated with RT (OR: 2.53, 95% CI: 1.35-4.72, P = .004). Furthermore, those who had Squamous Cell Carcinoma (SCC) of the larynx were more likely to be treated with RT (OR: 1.57, 95% CI: 1.19-2.07, P = .01). The median follow-up for the entire cohort of patients was 11.9 months, with a follow-up of 12.9 months for patients who received chemotherapy and RT and 10.6 months for those who received chemotherapy alone.
The addition of RT to chemotherapy resulted in a median survival of 13.6 months (range: 1.0-141.2 months) compared to 11.3 months (range 1.0-113.1 months) for patients treated with chemotherapy alone. The addition of RT to chemotherapy was associated with superior 1-year (55% vs 47%), 2-year (32% vs 20%), 3-year (23% vs 12%), and 5-year (16% vs 7%) OS compared to chemotherapy alone ( Figure 1A , HR: 0.71, 95% CI: 0.66-0.77, P < .001).
On univariate analysis, addition of RT, lower Charlson score, primary site, earlier T classification, earlier N classification, and greater income were associated with improved OS. On multivariate analysis, the addition of RT to chemotherapy remained significantly associated with improved OS (Table 2 . HR: 0.71, 95% CI: 0.61-0.82, P < .001).
Propensity score matching was utilized in order to reduce bias due to covariates which may influence the treatment effect. A total of 1099 patients who received chemotherapy alone were matched with 1099 patients who received RT in addition to chemotherapy. Baseline characteristics of the propensity matched cohorts are shown in Supporting Information Table S1 . After propensity score analysis, median survival was 13.6 months in the RT arm compared to FIGURE 1 Kaplan-Meier curves for overall survival (OS) for the entire cohort (A) and after propensity score matching (B) 11.3 months in patients who received chemotherapy only. The addition of RT to chemotherapy was associated with superior 1-year (56% vs 47%), 2-year (33% vs 21%), 3-year (25% vs 13%), and 5-year (16% vs 8%) OS when compared to chemotherapy alone ( Figure 1B , log-rank P < .001). On multivariate analysis, the addition of RT remained associated with improved OS in our propensity-matched cohort (Supporting Information Table S2 ). Landmark analysis continued to demonstrate an improvement in OS at 3, 6, and 12 month sequential time points (Figure 2A -C, all P < .001). On subgroup analysis, patients with early and advanced T and N classifications as well as all primary sites of the head and neck benefited from RT (Figure 3) .
Given the association of RT and OS, we hypothesized that delivering a higher BED would result in improved 10 . One-year, 3-year, and 5-year OS were 64%, 29%, and 19%, respectively, for those who were treated with a BED ≥ 72 Gy 10 compared to 49%, 20%, and 13% for those who received BED < 72 Gy 10 ( Figure 4 , HR: 0.78, 95% CI: 0.72-0.85, log-rank P < .001).
| DISCUSSION
Although the management of metastatic HNSCC continues to evolve, systemic therapies remain the standard of care. Nevertheless, a significant proportion of patients with metastatic HNSCC have symptomatic progression of locoregional head and neck disease, leading to progressive pain, bleeding, respiratory obstruction, cachexia, and death. 15 With the lack of high-quality evidence regarding the efficacy of RT in the metastatic setting, we sought to utilize the NCDB database to examine the impact of RT in the up-front management of patients with metastatic HNSCC. Our study demonstrated a 2.3 months improvement in OS and a 29% reduction in the relative risk of death with the addition of Landmark analyses limited to patients who survived at least 3 (A), 6 (B), and 12 (C) months RT to chemotherapy in the up-front management of patients with metastatic HNSCC. This improvement in median survival is similar to the benefit in survival seen from the addition of nivolumab which resulted in a 2.4-month improvement in OS for patients with platinum-refractory, recurrent HNSCC (including metastatic disease) compared to those treated with standard single-agent therapy with weekly methotrexate, docetaxel, or cetuximab. 16 The benefit in OS with the addition of RT was consistent on univariate, multivariate, propensity score matching, and landmark analysis, indicating the robustness of this association. Furthermore, subgroup analysis demonstrated that the benefit for the addition of RT was consistent across all subgroups including the different primary tumor sites of the head and neck. A recent analysis of the NCDB demonstrated that intensification of treatment with either surgical resection or definitive RT was associated with improved survival and supports our results.
14 In this study, survival outcomes were similar to our findings favoring the local treatment cohort. Another retrospective study of 408 patients with nasopharyngeal cancer demonstrated a survival benefit with the up-front use of radiotherapy with systemic therapy, 17 further supporting our findings.
To the best of our knowledge, this is the first study to demonstrate a survival benefit for the use of RT in the initial management of metastatic HNSCC. No randomized evidence exists to guide the use of local therapy in metastatic HNSCC patients with distant disease. One retrospective series demonstrated a median survival of 5.2 months for patients with advanced HNSCC, 38% of which had metastatic disease, who were treated with palliative RT. In their multivariate analysis, radiation dose was an independent predictor of OS and treatment response. 18 In another study, patients with incurable head and neck cancer who had an initial 50% objective regression of tumor to 20 Gy in 5 fractions were given further RT to 70 Gy. The median survival in this cohort was 400 days (approximately 33 months) compared to 200 days for the other patients. 19 Another large albeit older retrospective series of 1379 nasopharynx patients demonstrated an improvement in OS with increasing nasopharynx dose. 20 Although these series suggest a benefit to the use of RT in the metastatic setting, the small number of patients enrolled in these studies combined with inherent treatment bias makes it difficult to make any definitive conclusions regarding the benefit of RT. Our study differs from the evidence in the current literature in several ways: (1) we utilized a large national database to generate the largest single study cohort of patients given chemotherapy with or without radiotherapy in the treatment of metastatic HNSCC; (2) We used relatively sophisticated case-control propensity based matching to account for unmatched co-variates between the groups. The benefit in OS associated with local treatment in this study is in line with a growing body of literature showing the benefit of primary tumor control in several tumor types with metastatic disease, including prostate and small cell lung cancer. 21, 22 Certainly, in the case of HNSCC, optimizing locoregional control using altered fractionation, the addition of radio-sensitizing chemotherapy, or the addition of biologic agents has resulted in improvements in survival. The DAHANCA 6&7 trial demonstrated that a 6 fraction weekly regimen of RT improved both 5-year locoregional control and disease-free survival rates compared to 5 fraction weekly treatment. 23 The GORTEC 94-01 trial demonstrated an improvement in both locoregional control and OS with concomitant chemotherapy-RT compared with RT alone. 24 These data have been further supported by the MACH-NC meta-analysis, which demonstrated an improvement in survival with the use of both chemotherapy and RT compared to RT alone. 25 This benefit in survival from the use of therapies that optimize locoregional control has been demonstrated across several subsites including nasopharynx, larynx, oropharynx, oral cavity, and hypopharynx. 2, 3, 26, 27 Despite the benefit in OS for the addition of RT in patients with metastatic HNSCC, its routine use for these patients needs to be carefully balanced with the potential side effects of RT including mucositis, dermatitis, xerostomia, long-term dysphagia, PEG tube dependence, as well as inconvenience of receiving daily RT treatments. Given the incurable nature of patients with metastatic HNSCC, an attempt to deliver aggressive treatment such as chemotherapy-RT needs to be balanced with careful consideration of QOL for patients after treatment. Alternatively, use of hypofractionated RT and Stereotactic Body Radiation Therapy (SBRT) regimens that can be delivered in 1-3 weeks instead of 6-7 weeks to treat smaller target volumes focusing on gross disease represent potentially attractive treatment modalities for patients with metastatic head and neck tumors. Although RT doses with BEDs higher than 72 Gy were most beneficial with a hazard ratio of 0.73, most patients received this regimen in a protracted 7-week course. In addition to the advantage of short treatment course using hypofractionated RT and SBRT, overall response rates appear to be comparable to conventional fractionated RT and there is a potential for exploitation of alternate mechanisms of cell kill and tumor control, which might be highly relevant for patients with metastatic disease. 28 For example, there is emerging evidence that RT may act as an in situ vaccine and enhance the cytotoxic killing of tumors. Several preclinical studies have demonstrated enhanced immunogenic cell death with the addition of irradiation. 29, 30 Furthermore, evidence of an abscopal effect has been seen in the preclinical and clinical setting and may further enhance the improvement in survival. 31, 32 There are several limitations that must be acknowledged in this study. First, given the retrospective nature of this study, it is difficult to account for selection bias, which can significantly impact the patients who received RT and the subsequent dose they were given. We attempted to use multivariate and propensity-based matching to account for this, but there is still a possibility that this bias may have affected our results. Second, given that outcomes data are limited to OS, we were unable to collect important data on cause specific survival and locoregional recurrence. Third, specific details regarding chemotherapy agents, other than whether single versus multiagent chemotherapy was used, were not available from the NCDB. It is possible that physicians who prefer treatment with less side effects (ie, without up-front RT) would also be more likely to use chemotherapy with less side effects and thus different and often less potent drugs. However, in this cohort, patients who did not receive up-front RT were more likely to receive multiagent chemotherapy (56.8% vs 12.5%, P < .001; Table 1 ) and likely more aggressive systemic agents. Fourth, the extent and site of metastasis can influence the selection of patients who receive RT. Although we included these variables in our multivariate and propensity analysis, the true burden of metastasis is difficult to ascertain from this database. Finally, data regarding salvage therapies after failure of the first course of treatment are unavailable and can influence the outcomes of this study.
In conclusion, our study suggests a survival benefit for the addition of RT to chemotherapy in the up-front management of patients with metastatic HNSCC. Patients with good Eastern Cooperative Oncology Group performance status (ECOG 0-1) and oligometastatic disease with limited volume metastatic disease would be most likely to benefit from the addition of RT to chemotherapy. The optimal RT dose/ fractionation and treatment schedule should also be investigated further, potentially in a randomized trial comparing the addition of RT to standard systemic therapy and/or immunotherapy to optimize the therapeutic ratio for these patients.
